The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on the implementation of a NICE 30 day TA, TA871: Eptinezumab for preventing migraine. Proposed formulary position and RAG status are outlined in the consultation document.
Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC.
This consultation will run for three weeks and closes at 5pm on Friday 24th March 2023. Take part by visiting the consultations page.